Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division With the Acquisition of Warden Bio

Portfolio includes five investigational gene therapy programs for glycogen storage disorders that have no existing FDA-approved treatments available

Warden Bio Co-Founder Kunal Kishnani joins as President of Kriya’s Rare Disease Division and will lead its overall strategic, development, and partnership activities

Excerpt from the Press Release:

REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, announced today that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs. This acquisition serves as the foundation for Kriya’s Rare Disease Division focused on the discovery and development of gene therapies for rare diseases.

GSDs are a group of rare disorders caused by distinct single enzyme deficiencies involved in the synthesis or breakdown of glycogen. Warden Bio was established with a goal of comprehensively addressing multiple GSDs without approved therapies based on pioneering gene therapy technologies originally developed at Duke University. Currently, approved therapies are only available for one type of GSD, Pompe disease (GSD II).

“We are incredibly enthusiastic about the compelling research that has led to the development of Warden Bio’s pioneering gene therapies for GSDs,” said Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya. “This acquisition and the establishment of our Rare Disease Division align with our commitment to accelerating the advancement of best-in-class gene therapies. Kriya’s technology and manufacturing platforms uniquely position our company to drive meaningful progress to address a group of diseases in desperate need of new and better treatments.”

Together with the acquisition, Warden Bio Co-Founder Kunal Kishnani is joining Kriya as President of its Rare Disease Division, where he will lead overall strategic, development, and partnership activities. Prior to founding Warden Bio, Mr. Kishnani was a member of the corporate development team at Roivant Sciences, where he was responsible for helping to evaluate and negotiate new investment opportunities and strategic alliances. Mr. Kishnani also previously served as Co-Founder and Head of Operations at Genevant, where he was instrumental in driving key milestones for the company, including its launch, establishment of business operations, and execution of multiple collaborations with major pharmaceutical companies. Mr. Kishnani has degrees in finance and accounting from Elon University.

Click the button below to read the entire Press Release:

Continue Reading The Press Release